Results 71 to 80 of about 279,790 (190)

Functional impairment of human resident cardiac stem cells by the cardiotoxic antineoplastic agent trastuzumab [PDF]

, 2012
Trastuzumab (TZM), a monoclonal antibody against the ERBB2 protein, increases survival in ERBB2-positive breast cancer patients. Its clinical use, however, is limited by cardiotoxicity. We sought to evaluate whether TZM cardiotoxicity involves inhibition
A. c. Wolff, A. s. Barth, A. s. Ho, B. O'Rourke, CHIMENTI, ISOTTA, D. r. Davis, E. Kizana, E. Marban, G. Gerstenblith, I. Terrovitis, R. r. Smith, T. s. Li, Y. Zhang   +12 more
core   +1 more source

CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon

Frontiers in Immunology
Although current treatments for autoimmune diseases can effectively control symptoms, they rarely lead to cures and often require lifelong use, accompanied by considerable adverse effects.
Dehong Wu, Dehong Wu, Zijun Y. Xu-Monette, Jia Zhou, Kepeng Yang, Xinchang Wang, Yongsheng Fan, Ken H. Young, Ken H. Young   +8 more
doaj   +1 more source

CAR-T Cell Therapy for Follicular Lymphomas.

Mediterranean journal of hematology and infectious diseases
Follicular lymphoma is the second most diagnosed lymphoma in Western Europe. Significant advancements have considerably improved the survival of FL patients. However, 10-20% of these patients are refractory to standard treatments, and most of them will relapse.
Testa U., D'Alo' F., Pelosi E., Castelli G., Leone G.   +4 more
openaire   +3 more sources

K12-ligand-based CAR T cell therapy for CD7-positive T cell malignancies

Molecular Therapy: Oncology
Chimeric antigen receptor (CAR)-based therapy is of interest for relapsed or refractory (r/r) T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphomas. A prominent target antigen for this is the receptor CD7, which is expressed in ∼95% of T-ALL, ∼
Nienke Visser, Macarena González-Corrales, Jimena Álvarez-Freile, Maurien G. Pruis, Lena Rockstein, Harm Jan Lourens, Jan Jacob Schuringa, Tom van Meerten, Gerwin Huls, Edwin Bremer   +9 more
doaj   +1 more source

Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting S. typhimurium A1-R is superior to first-line chemotherapy. [PDF]

, 2018
Cancer of unknown primary (CUP) is a recalcitrant disease with poor prognosis because it lacks standard first-line therapy. CUP consists of diverse malignancy groups, making personalized precision therapy essential. The present study aimed to identify an
Chishima, Takashi, Eilber, Fritz C, Endo, Itaru, Hiroshima, Yukihiko, Hoffman, Robert M, Igarashi, Kentaro, Kawaguchi, Kei, Kiyuna, Tasuku, Li, Yunfeng, Matsuyama, Ryusei, Miyake, Kentaro, Miyake, Masuyo, Momiyama, Masashi, Murakami, Takashi, Nelson, Scott D, Razmjooei, Sahar, Russell, Tara A, Singh, Arun S, Singh, Shree Ram, Wangsiricharoen, Sintawat, Yoon, Sang Nam, Zhang, Zhiying   +21 more
core   +2 more sources

The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis

Frontiers in Oncology
IntroductionCD7 chimeric antigen receptor T-cell (CAR-T cell) therapy is an emerging method for treating hematological malignancies, and is another breakthrough in CAR-T cell therapy.MethodsThis study summarizes the currently published clinical research ...
Jile Liu, Yuxin An, Rui Sun, Xiaomei Zhang, Shujing Guo, Xuejin Gao, Mingfeng Zhao   +6 more
doaj   +1 more source

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer [PDF]

, 2012
A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly.
A Lundqvist, A Somers, C Berger, CA Tran, Carolina Berger, Cornelis JM Melief, Daniel J Powell, David F Stroncek, DG Song, DJ Powell Jr, DL Porter, Francesco M Marincola, G Mostoslavsky, GG Kenter, Gustavo Mostoslavsky, J Jin, J Staerk, James R Heath, Jeffrey S Miller, JN Kochenderfer, JN Kochenderfer, John O'Shea, JS Miller, K Takahashi, L Gattinoni, L Gattinoni, L Gattinoni, L Gattinoni, LA Johnson, Luca Gattinoni, M Kalos, M Kalos, M Kalos, Mahendra Rao, Mark E Dudley, Martin A Cheever, ME Dudley, ME Dudley, Michael Kalos, Nicholas P Restifo, P Muranski, Peter Flynn, PF Robbins, RA Morgan, Richard W Childs, SA Rosenberg, Steven A Rosenberg, TS Park, X Wang   +48 more
core   +4 more sources

The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity [PDF]

, 2017
The primary aim of this clinical trial was to determine the feasibility of delivering first-generation CAR T cell therapy to patients with advanced, CEACAM5(+) malignancy.
Austin, E, Burt, DJ, Byatte, AJ, Chester, KA, Gilham, DE, Guest, RD, Halford, SER, Hawkins, RE, Kirillova, N, Nabarro, S, Pillai, M, Rothwell, DG, Sharma, SK, Thistlethwaite, FC, Valle, JW, Wan, S, Westwood, NB   +16 more
core  

Application of CAR-T cells in cancer gene therapy [PDF]

, 2018
Genska terapija predstavlja obećavajući terapijski alat za liječenje onih bolesti koje se konvencionalnim metodama liječenja nisu uspješno uspijele eliminirati.
Krmpotić, Klara
core   +2 more sources

Potential role of immunotherapy in advanced non-small-cell lung cancer [PDF]

, 2016
Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib ...
Antoniou, Georgios, Catarina, Paulo Esrom, De Mello, Ramon Andrade, Nadine, Sara, Veloso, Ana Flavia   +4 more
core   +3 more sources